Highly Sensitive Cardiac Troponin I Levels in Peripheral Blood Predict CV Events in Patients with RA
Long-Term Efficacy and Safety Results of SIRROUND-D Trial of Sirukumab in Patients with Active RA Despite DMARD Treatment
In this long-term efficacy and safety analysis of the global phase 3 SIRROUND-D trial, improvements in signs and symptoms of rheumatoid arthritis (RA) and health-related physical and emotional well-being were maintained with sirukumab treatment in patients with active RA despite disease-modifying antirheumatic drugs (DMARDs).
Upadacitinib (ABT-494) Is Effective in Patients with Active RA with Inadequate Response to Conventional Synthetic DMARDs
Results of the randomized, placebo-controlled, phase 3 SELECT-NEXT study showed that upadacitinib, a selective JAK-1 inhibitor, at 15 mg and 30 mg once daily, was efficacious in patients with rheumatoid arthritis (RA) who had inadequate response to conventional synthetic disease-modifying antirheumatic drugs (DMARDs), with a safety and tolerability profile that was consistent with that previously reported.
An updated integrated analysis of patients (n = 3492) with moderately to severely active rheumatoid arthritis (RA), including patients exposed to any dose of baricitinib for up to 5.5 years, showed that the safety profile of baricitinib was maintained as similar to that previously reported.
Suboptimal EHR Reporting of Clinical Measures in RA Patients Receiving a Biologic or Targeted Synthetic DMARD
A real-world analysis of electronic health record (EHR) databases across Integrated Delivery Networks showed lower EHR reporting rates of clinical and disease severity measures, thus compromising the ability of rheumatologists to adopt a guideline-recommended treat-to-target approach in clinical practice.
Both Tofacitinib and Baricitinib in Combination with Methotrexate Are Efficacious in Patients with RA
Results from a systematic review and network meta-analysis of randomized controlled trials showed that tofacitinib 10 mg and baricitinib 8 mg combined with methotrexate were both effective in patients with rheumatoid arthritis (RA), with similar safety outcomes.
No Increased Cardiovascular Risk in Patients with RA Who Newly Initiated Tocilizumab versus Abatacept
A large multidatabase, population-representative cohort study showed a similar risk for primary composite cardiovascular events between patients with rheumatoid arthritis (RA) who newly started tocilizumab and abatacept starters.
Long-Term Efficacy and Safety with Ibrutinib in Previously Treated CLL: Up to 4 Years’ Follow-Up of the RESONATE Study
This 4-year follow-up of the phase 3 RESONATE study provides updated data on the efficacy and safety of ibrutinib, comparing the long-term efficacy and safety of ibrutinib versus ofatumumab in patients with chronic lymphocytic leukemia (CLL).
Page 2 of 8
Results 11 - 20 of 80
Results 11 - 20 of 80